Background: Infliximab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). The manufacturerrecommended administration is over 2 hours followed by 2 hours of patient observation. The data relating to adverse outcomes in patients receiving accelerated infusions for IBD
Peripheral neuropathy with infliximab therapy in inflammatory bowel disease
β Scribed by D.C. Burger; T.H.J. Florin
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 44 KB
- Volume
- 15
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Despite recent advances, the therapeutic armamentarium for inflammatory bowel disease (IBD) is still limited. In addition, a step-up approach is recommended for most IBD patients. Thus, optimizing each medical therapy before switching to another drug class is the rule in clinical practice. Conventio
## Abstract Inflammatory bowel disease (IBD) affects β1.4 million people in North America and, because of its typical early age of onset and episodic disease course, IBD patients often undergo numerous imaging studies over the course of their lifetimes. Computed tomography (CT) has become the stand